Marissa A Mencio1, Estrellita Ontiveros1, James S Burdick2, Steven G Leeds3. 1. Division of Minimally Invasive Surgery, Baylor University Medical Center at Dallas, 3500 Gaston Avenue, 1st Floor Roberts Hospital, Dallas, TX, 75246, USA. 2. Department of Gastroenterology, Baylor University Medical Center at Dallas, Dallas, USA. 3. Division of Minimally Invasive Surgery, Baylor University Medical Center at Dallas, 3500 Gaston Avenue, 1st Floor Roberts Hospital, Dallas, TX, 75246, USA. Steven.Leeds@BSWHealth.org.
Abstract
BACKGROUND: Perforations and anastomotic leaks of the gastrointestinal tract are severe complications, which carry high morbidity and mortality and management of these is a multi-disciplinary challenge. The use of endoluminal vacuum (EVAC) therapy has recently proven to be a useful technique to manage these complications. We report our institution's experience with this novel technique in the chest, abdomen, and pelvis. METHODS: This is a retrospective review of an IRB approved registry of all EVAC therapy patients from July 2013 to December 2016. A total of 55 patients were examined and 49 patients were eligible for inclusion: 15 esophageal, 21 gastric, 3 small bowel, and 10 colorectal defects. The primary endpoint was closure rate of the GI tract defect with EVAC therapy. RESULTS: Fifteen (100%) esophageal defects closed with EVAC therapy. Mean duration of therapy was 27 days consisting of an average of 6 endosponge changes every 4.8 days. Eighteen (86%) gastric defects closed with EVAC therapy. Mean duration of therapy was 38 days with a mean of 9 endosponge changes every 5.3 days. Three (100%) small bowel defects closed with EVAC therapy. Mean duration of therapy was 13.7 days with a mean of 2.7 endosponge changes every 4.4 days. Six (60%) colorectal defects closed with EVAC therapy. Mean duration of therapy was 23.2 days, consisting of a mean of 6 endosponge changes every 4.0 days. There were two deaths, which were not directly related to EVAC therapy and occurred outside the measured 30-day mortality. CONCLUSION: Our experience demonstrates that EVAC therapy is feasible and effective for the management of gastrointestinal perforations/leaks throughout the GI tract and can be considered as a safe alternative to surgical intervention in select cases.
BACKGROUND: Perforations and anastomotic leaks of the gastrointestinal tract are severe complications, which carry high morbidity and mortality and management of these is a multi-disciplinary challenge. The use of endoluminal vacuum (EVAC) therapy has recently proven to be a useful technique to manage these complications. We report our institution's experience with this novel technique in the chest, abdomen, and pelvis. METHODS: This is a retrospective review of an IRB approved registry of all EVAC therapy patients from July 2013 to December 2016. A total of 55 patients were examined and 49 patients were eligible for inclusion: 15 esophageal, 21 gastric, 3 small bowel, and 10 colorectal defects. The primary endpoint was closure rate of the GI tract defect with EVAC therapy. RESULTS: Fifteen (100%) esophageal defects closed with EVAC therapy. Mean duration of therapy was 27 days consisting of an average of 6 endosponge changes every 4.8 days. Eighteen (86%) gastric defects closed with EVAC therapy. Mean duration of therapy was 38 days with a mean of 9 endosponge changes every 5.3 days. Three (100%) small bowel defects closed with EVAC therapy. Mean duration of therapy was 13.7 days with a mean of 2.7 endosponge changes every 4.4 days. Six (60%) colorectal defects closed with EVAC therapy. Mean duration of therapy was 23.2 days, consisting of a mean of 6 endosponge changes every 4.0 days. There were two deaths, which were not directly related to EVAC therapy and occurred outside the measured 30-day mortality. CONCLUSION: Our experience demonstrates that EVAC therapy is feasible and effective for the management of gastrointestinal perforations/leaks throughout the GI tract and can be considered as a safe alternative to surgical intervention in select cases.
Authors: Norbert Hüser; Christoph W Michalski; Mert Erkan; Tibor Schuster; Robert Rosenberg; Jörg Kleeff; Helmut Friess Journal: Ann Surg Date: 2008-07 Impact factor: 12.969
Authors: Maciej Borejsza-Wysocki; Krzysztof Szmyt; Adam Bobkiewicz; Stanisław Malinger; Józef Świrkowicz; Jacek Hermann; Michał Drews; Tomasz Banasiewicz Journal: Wideochir Inne Tech Maloinwazyjne Date: 2015-06-08 Impact factor: 1.195
Authors: Chengcheng Christine Zhang; Lukas Liesenfeld; Rosa Klotz; Ronald Koschny; Christian Rupp; Thomas Schmidt; Markus K Diener; Beat P Müller-Stich; Thilo Hackert; Peter Sauer; Markus W Büchler; Anja Schaible Journal: BMC Gastroenterol Date: 2021-02-16 Impact factor: 3.067
Authors: Sonia Fernández-Ananín; Eulalia Ballester; Carlos Guarner Argente; Carmen Balague; Eduard M Targarona Journal: Gastroenterol Rep (Oxf) Date: 2020-07-20